Evaluation of spin in oncology clinical trials.
Abstracts
Bias
Overall survival
Randomized controlled trial
Spin
Surrogate endpoints
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
19
02
2019
revised:
08
10
2019
accepted:
14
10
2019
pubmed:
17
11
2019
medline:
8
2
2020
entrez:
17
11
2019
Statut:
ppublish
Résumé
Spin, the misrepresentation of research findings, in clinical trial abstract has been shown to influence how oncologist rate a drug's efficacy. We searched PubMed for clinical trials published in ten key journals in 2017. Our primary objectives were to assess the frequency and manifestations of spin in the abstracts of those clinical trials that measured both overall survival and at least one surrogate efficacy endpoints. 124 trials were included for analysis. We found evidence of spin in 46 of 124 (37.1%, 95% CI 29.1%-45.9%) trial abstracts. Spin in the abstract results was most often due to authors emphasizing a statistically significant subgroup analysis (n = 6). Spin in the abstract conclusions was most often due to authors relying on a statistically significant surrogate endpoint to highlight the bioefficacy of the intervention (n = 17). Spin is prevalent in the abstracts of oncology clinical trials that measure OS and a surrogate endpoint. The conclusion sections of abstracts were most prone to contain spin. When OS was the primary endpoint, spin was primarily used to distract from the nonsignificant OS data. To mitigate unintentional hype for cancer therapies, we recommend authors structure their conclusions around patient-important outcomes.
Identifiants
pubmed: 31733444
pii: S1040-8428(19)30193-3
doi: 10.1016/j.critrevonc.2019.102821
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102821Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.